Market open · Delayed intraday data · 3:21 PM ET
Last update: Nov 18, 2026, 3:02 PM ET
Madrigal Pharmaceuticals, Inc.
▼ 11.8% on Nov 3, 2026

Why Madrigal Pharmaceuticals, Inc. (MDGL) Stock Fell 11.8% on Nov 3, 2026

Researched by BestStocks Market Desk · Published Nov 3, 2026
Prior close
$431.16
Nov 3, 2026 close
$396.32
Change
−$34.84
-8.08%
Rel. volume
7.2×
2.0M shares

What happened

Valuation-8.1%high confidence

Madrigal Pharmaceuticals reported Q3 2026 earnings that beat both earnings and revenue estimates (per Zacks and Globe Newswire), yet the stock fell 5.57% to $407.17 on elevated volume of 891,384 shares (4.87x typical for this time of day). The divergence between positive results and intraday selling suggests investors may have focused on forward guidance or margin concerns rather than the beat itself.

Source: fmp_intraday
What to watch next

Monitor for analyst commentary and rating changes in the coming sessions; track next earnings date (tentatively February 18, 2027) and watch for any management guidance revisions or pipeline announcements that might explain today's divergent reaction.

Other developments that session

Material / Earnings-11.8%high confidence

Madrigal Pharmaceuticals, Inc. (MDGL) moved -11.80% from $449.32 to $396.32 on 2026-11-03 after reporting Q3 2026 earnings. MDGL reported EPS of $1.83, beating the consensus estimate of -$0.86 by 312.01%. Volume was elevated at 6.5x the 5-day average.

Source: daily_prices:fmp_change_percent
Material / Earnings+312.1%high confidence

Madrigal Pharmaceuticals, Inc. (MDGL) reported EPS of $1.83 vs. consensus estimate of -$0.86, beating by 312.1% on November 3, 2026.

Source: earnings_events
Filingshigh confidence

Madrigal Pharmaceuticals, Inc. (MDGL) filed a new 10-Q on November 3, 2026.

Source: filing_snapshots
News

MDGL reported Q3 EPS of $1.83, beating consensus estimate of -$1.09 loss.

Source: Zacks

Frequently asked questions

Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock fall on Nov 3, 2026?

Madrigal Pharmaceuticals reported Q3 2026 earnings that beat both earnings and revenue estimates (per Zacks and Globe Newswire), yet the stock fell 5.57% to $407.17 on elevated volume of 891,384 shares (4.87x typical for this time of day). The divergence between positive results and intraday selling suggests investors may have focused on forward guidance or margin concerns rather than the beat itself.

How much did MDGL stock fall on Nov 3, 2026?

MDGL fell 11.8% during the Nov 3, 2026 trading session.

This is an archived analysis of MDGL's Nov 3, 2026 session.
See MDGL's latest changes →
Educational research tool — not personalized investment advice. Figures reflect the Nov 3, 2026 session as first analyzed.